Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
Bhatnagar T, Chaudhuri S, Ponnaiah M, Yadav PD, Sabarinathan R, Sahay RR, Ahmed F, Aswathy S, Bhardwaj P, Bilimale A, Kumar MS, Logaraj M, Narlawar U, Palanivel C, Patel P, Rai SK, Saxena V, Singh A, Thangaraj JW, Agarwal A, Alvi Y, Amoghashree, Ashok P, Babu D, Bahurupi Y, Bhalavi S, Behera P, Biswas PP, Charan J, Chauhan NK, Chetak KB, Dar L, Das A, Deepashree R, Dhar M, Dhodapkar R, Dipu TS, Dudeja M, Dudhmal M, Gadepalli R, Garg MK, Gayathri AV, Goel AD, Gowdappa HB, Guleria R, Gupta MK, Islam F, Jain M, Jain V, Jawahar MLS, Joshi R, Kant S, Kar SS, Kalita D, Khapre M, Khichar S, Kombade SP, Kohli S, Kumar A, Kumar A, Kumar D, Kulirankal KG, Leela KV, Majumdar T, Mishra B, Misra P, Misra S, Mohapatra PR, Murthy MN, Nyayanit DA, Patel M, Pathania M, Patil S, Patro BK, Jalandra R, Rathod P, Shah N, Shete A, Shukla D, Shwethashree M, Sinha S, Sumana MN, Surana A, Trikha A, Tejashree A, Venkateshan M, Vijaykrishnan G, Wadhava S, Wig N, Gupta N, Abraham P, Murhekar MV.
Bhatnagar T, et al. Among authors: kant s.
Int J Infect Dis. 2022 Sep;122:693-702. doi: 10.1016/j.ijid.2022.07.033. Epub 2022 Jul 16.
Int J Infect Dis. 2022.
PMID: 35843496
Free PMC article.